Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pontocerebellar hypoplasias (PCH) are a rare heterogeneous group of diseases characterized by hypoplasia and atrophy and/or early neurodegeneration of the cerebellum and pons. Eight subtypes named type 1-8 have been described, generally inherited in an autosomal recessive pattern.
No HPO annotations are available for this condition.
Age of onset: at birth, newborn period, before birth, adolescence, childhood, infancy.
To date, at least 131 individuals have been identified with TSEN54 pontocerebellar hypoplasia (TSEN54-PCH) . The phenotypic spectrum of TSEN54-PCH comprises the three PCH phenotypes (PCH 2, 4, and 5) thought to be distinct entities before their molecular basis was known. The main difference between the three PCH phenotypes is life expectancy: individuals with PCH2 usually survive into childhood, whereas those with PCH4 and PCH5 usually die as neonates. Pontocerebellar Hypoplasia Type 2 The following description of the phenotypic features associated with TSEN54-PCH type 2 is based on . Table 2. Select Features of TSEN54 Pontocerebellar Hypoplasia Type 2
The phenotypic spectrum of TSEN54 pontocerebellar hypoplasia (TSEN54-PCH) includes three PCH phenotypes (thought to be distinct entities before the molecular basis of PCH was known) based on neuroradiologic and neurologic findings: PCH type 2 (PCH2), PCH type 4 (PCH4), and PCH type 5 (PCH5).
TSEN54-PCH should be suspected in children with severe neurologic impairment and the following findings on brain imaging .
Brain MRI Findings
Common findings
No approved treatments are currently available for pontocerebellar hypoplasia. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for pontocerebellar hypoplasia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for pontocerebellar hypoplasia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 6.
Recommended Surveillance for Individuals with TSEN54 Pontocerebellar Hypoplasia Type 2
System/Concern | Evaluation | Frequency
| Assess airway pulmonary function secretion management. | Monitoring of respiratory function may be needed to detect sleep apnea.
Gastrointestinal/
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
192 publications have been identified in PubMed for pontocerebellar hypoplasia. Research spans Case Report / Case Series (36%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 69 | 36% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 10:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Feature | % of Personswith Feature | Comment |
|---|---|---|
Severe developmental delay | 100% | — |
Neurologic | Choreoathetosis | 88% |
Pure spasticity | 12% | — |
Epileptic seizures | 82% | — |
Dystonic attacks | 33% | — |
Gastrointestinal | Feeding difficulties | 100% |
GERD | 73% | — |
Sleep disorder | 96% | — |
Apnea | 67% | — |
Recurrent infections | 52% | Based on 33 individuals homozygous for the common missense variant, p.Ala307Ser, from nonconsanguineous parents surviving until age 11 years Pregnancy is usually unremarkable. Newborns have no external dysmorphic features and no visceral abnormalities. |
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
Table 3. Genes of Interest in the Differential Diagnosis of TSEN54 Pontocerebellar Hypoplasia
Gene(s) | Phenotype/Disorder | MOI | Brain MRI Findings | Clinical Characteristics |
|---|---|---|---|---|
B3GALNT2B4GAT1DAG1FKRPFKTNGMPPBISPDLARGE1POMGNT1POMGNT2POMKPOMT1POMT2RXYLT11 | Alpha-dystroglycanopathies | AR | Wide spectrum of brain malformations incl cobblestone lissencephaly hydrocephalus | Muscle weakness ophthalmologic abnormalities |
CASK | ID microcephaly w/pontine cerebellar hypoplasia (See CASK Disorders.) | XL | Neocortical dysplasia (simplified gyral pattern, thin brain stem w/flattening of the pons) severe cerebellar hypoplasia (pontocerebellar hypoplasia) | Heterozygous females have severe or profound ID structural brain anomalies incl mild congenital microcephaly severe postnatal microcephaly.; Hemizygous males are more severely affected. |
CHMP1A | PCH82 | AR | MRI findings similar to those of PCH2 | Microcephaly, delayed walking, variable foot deformities, chorea, dystonic posturing, impaired cognition EXOSC3 EXOSC8 SLC25A46 |
VRK1 | PCH12,3 (See EXOSC3-PCH.) | AR | Pontine atrophy may not be present in some individuals. | Lower motor neuron deficits due to loss of anterior horn cells; manifestations of peripheral denervation incl weakness muscle hypotonia from birth; Mixed central (spastic, dystonic) peripheral pareses may be present in those w/prolonged survival; some children w/PCH1 die at an early age.4 |
40 genes (e.g., PMM25) | Congenital disorders of glycosylation (CDG); see also PMM2-CDG (CDG-Ia). | AR(XL) | Pontocerebellar hypoplasia w/superimposed atrophy, delayed myelination | Dysmorphic features, ataxia, organ failure in neonatal period |
PCLO | PCH32 | AR | — | — |
RARS2 | PCH62 | AR | Very rare; CSF lactate concentration | — |
RELN | Lissencephaly 2 (OMIM 257320) | AR | Classic lissencephaly w/coexistent cerebellar pontine hypoplasia | — |
SEPSECS | PCH22 | AR | Progressive cerebello-cerebral atrophy closely resembles mild PCH2. | Clinical findings closely resemble mild PCH2. |
TOE1 | PCH72 | AR | PCH | Disorders of sex development VLDLR |
VLDLR cerebellar hypoplasia | AR | Gross cerebellar hypoplasia, a flat ventral pons, simplified gyri | Ataxia ID AR = autosomal recessive; ID = intellectual disability; MOI = mode of inheritance; PCH = pontocerebellar hypoplasia; XL = X-linked 1. OMIM Phenotypic Series: Muscular dystrophy-dystroglycanopathy, type A 2. 3. | — |
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
Biomarker and diagnostic research for pontocerebellar hypoplasia has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
vatiquinone | vatiquinone | PTC Therapeutics, Inc. | 2017 | — | Designated |
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with TSEN54 pontocerebellar hypoplasia (TSEN54-PCH), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Note that recommendations are based only on PCH2 caused by homozygosity for theTSEN54 pathogenic variant , as all other subtypes are very rare. Table 4. Recommended Evaluations Following Initial Diagnosis of TSEN54 Pontocerebellar Hypoplasia Type 2
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measure length, weight. | See Gastrointestinal/Feeding recommendations if there is evidence of failure to thrive. Gastrointestinal/ |
Feeding | Gastroenterology / nutrition / feeding team eval | Assess swallowing feeding to determine safety of oral vs gastrostomy feeding. |
Respiratory | Assess airway pulmonary function secretion management. | Consult pulmonologist. |
Neurologic | Eval by pediatric neurologist | Assess for evidence of severe generalized clonus; chorea, spasticity; seizures; impaired central vision. |
Musculoskeletal | Multidisciplinary neuromuscular clinic assessment by orthopedist, physical medicine, OT/PT | To incl assessment of:; Contractures, clubfoot, kyphoscoliosis; Need for positioning devices |
Palliative care | Refer to palliative care specialist. | When deemed appropriate by family care providers Genetic |
counseling | By genetics professionals1 | To inform affected individuals their families re nature, MOI, implications of TSEN54-PCH2 to facilitate medical personal decision making Family support/ resources |
Treatment of Manifestations in Individuals with TSEN54 Pontocerebellar Hypoplasia Type 2 Manifestation/Concern | Treatment | Considerations/Other |
Seizures | Per standard practice | By neurologist experienced in epilepsy management |
Irritability | None | Often related to chorea (involuntary movements) |
Musculoskeletal | Multidisciplinary neuromuscular clinic physical medicine, OT/PT | Maximize gross motor fine motor skills through PT/OT use of adaptive devices.; Alternative casting/splinting stretching Orthopedics |
Dysphagia | Gastroenterology / nutrition / feeding team | Modify food consistency to aspiration risk /or consider NG feeding gastrostomy. |
Speech | Speech/language eval | Consider involving speech therapist OT to improve communication skills. |
Respiratory | Manage pulmonary complications; treatment of respiratory infections | Per treating pulmonologist |
Neurodevelopmental | Early intervention / individual education program based on needs | See . NG = nasogastric, OT = occupational therapy, PT = physical therapy The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. |
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
Although hyperthermic episodes have been documented in individuals with PCH2, no special risk appears to be associated with generalized anesthesia.
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
1 trial found
|
Aspiration risk nutritional status
Monitor for constipation.
| Annually; more frequently if needed
|
PT/OT eval
Assessment for contractures, scoliosis, foot deformities.
Hip/spine x-rays
|
Monitor those w/seizures as clinically indicated.
Monitor for dystonia choreic movements.
| Monitor developmental milestones.
Family support
resources | Family needs
OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "TSEN54 Pontocerebellar Hypoplasia"
Estimated prevalence: Unknown (Unknown prevalence).
Research summaries |
41 |
21% |
Laboratory research | 41 | 21% |
Disease patterns and progression | 19 | 10% |
Testing and diagnosis research | 12 | 6% |
New treatment approaches | 6 | 3% |
Clinical study results | 3 | 2% |
Other research | 1 | 1% |
Mirfendereski S (2026). [PMID: 41693725](https://pubmed.ncbi.nlm.nih.gov/41693725/). *Iranian journal of child neurology*. [Diagnostic / Biomarker]
Yuen M (2026). [PMID: 42045457](https://pubmed.ncbi.nlm.nih.gov/42045457/). *Acta Neuropathol*. [Basic Science / Preclinical]
Hwang S (2026). [PMID: 41152456](https://pubmed.ncbi.nlm.nih.gov/41152456/). *J Hum Genet*. [Epidemiology / Natural History]
Rezaei Z (2026). [PMID: 41825724](https://pubmed.ncbi.nlm.nih.gov/41825724/). *European journal of medical genetics*. [Review / Meta-Analysis]
Higginson LA (2026). [PMID: 41417727](https://pubmed.ncbi.nlm.nih.gov/41417727/). *Cell reports*. [Basic Science / Preclinical]
Lin X (2026). [PMID: 41621844](https://pubmed.ncbi.nlm.nih.gov/41621844/). *Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics*. [Case Report / Case Series]
Bonardi CM (2026). [PMID: 41530147](https://pubmed.ncbi.nlm.nih.gov/41530147/). *Nature communications*. [Case Report / Case Series]
Reynier P (2026). [PMID: 41640504](https://pubmed.ncbi.nlm.nih.gov/41640504/). *Neuro-ophthalmology (Aeolus Press)*. [Case Report / Case Series]
Wijeratne HRS (2026). [PMID: 41659589](https://pubmed.ncbi.nlm.nih.gov/41659589/). *bioRxiv : the preprint server for biology*. [Case Report / Case Series]
Herrmann A (2026). [PMID: 41875837](https://pubmed.ncbi.nlm.nih.gov/41875837/). *Pediatr Neurol*. [Diagnostic / Biomarker]
AI-curated news mentioning pontocerebellar hypoplasia
Updated May 23, 2026
Research identifies mutations in the TOE1 gene that impair its thermal stability, ribonuclease activity, and oligomerization, contributing to pontocerebellar hypoplasia. This discovery enhances understanding of the molecular mechanisms underlying this rare disease.
A study published in PubMed reveals novel genetic variants associated with pontocerebellar hypoplasia in an Iranian cohort. This research enhances understanding of the genetic underpinnings of this rare neurological disorder.